#samsungbioepis — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #samsungbioepis, aggregated by home.social.
-
Samsung Bioepis achieved record annual revenue in 2025, driven by strong biosimilar sales in the US and Europe, while expanding its pipeline and launching new products.
#YonhapInfomax #SamsungBioepis #BiosimilarSales #OperatingProfit #USMarket #RevenueGrowth #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=102036 -
Samsung Bioepis has dismissed speculation over a potential dual listing, as Samsung Biologics announces a spin-off to separate its CDMO and biosimilar businesses, emphasizing that an IPO for Bioepis is not under consideration.
#YonhapInfomax #SamsungBioepis #SamsungBiologics #SpinOff #CDMOBusiness #Biosimilar #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=64634 -
Samsung Bioepis has dismissed speculation over a potential dual listing, as Samsung Biologics announces a spin-off to separate its CDMO and biosimilar businesses, emphasizing that an IPO for Bioepis is not under consideration.
#YonhapInfomax #SamsungBioepis #SamsungBiologics #SpinOff #CDMOBusiness #Biosimilar #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=64634 -
Samsung Bioepis has dismissed speculation over a potential dual listing, as Samsung Biologics announces a spin-off to separate its CDMO and biosimilar businesses, emphasizing that an IPO for Bioepis is not under consideration.
#YonhapInfomax #SamsungBioepis #SamsungBiologics #SpinOff #CDMOBusiness #Biosimilar #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=64634 -
Samsung Bioepis has dismissed speculation over a potential dual listing, as Samsung Biologics announces a spin-off to separate its CDMO and biosimilar businesses, emphasizing that an IPO for Bioepis is not under consideration.
#YonhapInfomax #SamsungBioepis #SamsungBiologics #SpinOff #CDMOBusiness #Biosimilar #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=64634 -
Samsung Biologics clarifies it is not currently considering an initial public offering for its subsidiary Samsung Bioepis, dispelling market speculation
#YonhapInfomax #SamsungBiologics #SamsungBioepis #IPO #BiotechIndustry #CorporateStrategy #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=64302 -
Hanmi Pharmaceutical and Samsung Bioepis partner to launch Prolia biosimilar in South Korea, aiming to provide affordable osteoporosis treatment options through joint marketing efforts.
#YonhapInfomax #HanmiPharmaceutical #SamsungBioepis #ProliaBiosimilar #OsteoporosisTreatment #PharmaceuticalPartnership #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=54656